Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Nicolas Llosa

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2025
Nivolumab and Relatlimab for the treatment of patients with unresectable or metastatic mismatch repair proficient colorectal cancerEric S Christenson, Won Jin Ho, Daniel Shu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2025
Correction: Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal CancerEric S Christenson, Won Jin Ho, Daniel Shu, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 10, 2014
Microbiota organization is a distinct feature of proximal colorectal cancersChristine M Dejea, Elizabeth C Wick, Elizabeth M Hechenbleikner, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 19, 2025
Nivolumab and Relatlimab for the treatment of patients with unresectable or metastatic mismatch repair proficient colorectal cancerEric S Christenson, Won Jin Ho, Daniel Shu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 15, 2025
Correction: Nivolumab and Relatlimab for the Treatment of Patients with Unresectable or Metastatic Mismatch Repair-Proficient Colorectal CancerEric S Christenson, Won Jin Ho, Daniel Shu, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 10, 2014
Microbiota organization is a distinct feature of proximal colorectal cancersChristine M Dejea, Elizabeth C Wick, Elizabeth M Hechenbleikner, et al.
Pageof 2